Gina Mauro

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.

PFS was improved with belantamab mafodotin triplet for patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

Escalated adjuvant chemotherapy did not improve recurrence-free survival in patients with stage III colon cancer when using a ctDNA-informed approach.

The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.

The approved combination of enfortumab vedotin and pembrolizumab provides an alternative to chemotherapy for patients in China.

Arlo-cel yields responses among patient subgroups, including those with triple class–refractory disease and extramedullary disease.

The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Autologous transplant did not confer significantly improved overall survival regardless of induction intensity in a phase 3 trial.

For patients with relapsed/refractory diffuse large b-cell lymphoma, meaningful efficacy outcomes were shown with FS118.

Responses with epcoritamab were comparable across the expansion and optimization cohorts in the EPCORE CLL-1 trial.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.